Earlier, in February 2011, this major neuromodulation company received FDA approval for AspireHC, a new and improved generator to be used in vagus nerve stimulation (:VNS) therapy. However, later in ...

Cyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, ...

Cyberonics has made a minority investment in Cerbomed GmbH. The inital investment is €2 million (US$2.6 million) but that can total € 5.5 million, subject to the achievement of certain clinical ...

There's no foolproof way to know the future for Cyberonics (NAS: CYBX) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock ...

All cash flow is not created equal. Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because ...

— -- A: Cyberonics makes medical devices that are implanted to control disorders such as epilepsy and some forms of depression. Depending on when you bought this stock, you are probably either ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Cyberonics has hired a new chief executive from Boston Scientific, the medical instruments and supplies company that owns 14 percent of the Houston company's shares. Daniel Moore, who took over today, ...

Cyberonics, which makes a device that treats epilepsy, disclosed Monday it received a warning letter last month from the FDA citing problems inspectors found at its Houston manufacturing plant. The ...

Investors hope Cyberonics (NAS: CYBX) will top analyst estimates once again after beating predictions by $0.02 in the previous quarter. The company will unveil its latest earnings on Friday, Feb. 24.